Search
for
Sort by
Research
720-750 / 1000+ resultsresearch Supplementary data: Treatment of androgenetic alopecia with sublingual minoxidil in transgender people receiving testosterone
research Supplementary data: Treatment of androgenetic alopecia with sublingual minoxidil in transgender people receiving testosterone
research Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
Upadacitinib effectively treats severe alopecia areata and is safe.
research Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program
Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.
research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
research A multicentre cohort study of the clinicopathological features and treatment outcomes of fibrosing alopecia in a pattern distribution
Fibrosing alopecia can be stabilized or improved with anti-inflammatory treatments and hair growth agents.
research 61720 The effect of sublingual minoxidil on androgenetic alopecia in transgender individuals receiving testosterone for gender-affirmation: A 24-week single-centre double-blinded, randomized, placebo-controlled clinical trial
Sublingual minoxidil significantly improves hair growth in transgender individuals on testosterone therapy.
research Criteria for Commencing and Continuing Subsidised Janus Kinase Inhibitor Therapy in Australian Alopecia Areata Patients—Results From an Australian Expert Consensus Exercise
Experts created guidelines for who in Australia can get subsidized JAK inhibitor therapy for alopecia areata.
research You cannot go bald without first, losing your hair: Telogen effluvium is a precursor to, prerequisite for and potentially an incitant to common baldness in men
Hair loss (telogen effluvium) happens before male pattern baldness.
research Scalp hair repigmentation after radiotherapy
A 76-year-old man's grey hair turned back to its original color after radiotherapy.
research Patient satisfaction with hair regrowth in a study of ritlecitinib: a plain language summary
Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.
research COLLAB: A Global Survey of Clinical and Laboratory Assessment in Alopecia Areata by Hair Specialists
Hair specialists vary in testing for alopecia areata, highlighting the need for standard guidelines.
research Prediction of Long-term Scalp Hair Regrowth at 24 Months in Patients with Alopecia Areata Receiving Ritlecitinib Treatment in the ALLEGRO Clinical Trial Program
research Pericardial Disorders Occurring during Open Label Study of 3747 Patients Treated with Systemic Minoxidil
Low-dose oral minoxidil is safe for the heart.
research Combination of oral minoxidil and bicalutamide for the treatment of female pattern hair loss in adolescents
Combining oral minoxidil and bicalutamide may help improve hair growth in adolescent girls.
research Evidence-Based Data on How Long to Treat to Achieve Treatment Response With Baricitinib in Severe Alopecia Areata
Baricitinib treatment for severe alopecia areata shows significant improvement by 52 weeks, especially in very severe cases.
research Sublingual Minoxidil Increases Fibre Diameter in Male Androgenetic Alopecia. - A proxy for Reversal of Hair Follicle Miniaturization.
Sublingual minoxidil increases hair thickness in men with hair loss.
research Sublingual Minoxidil 5 mg versus Oral Minoxidil 5 mg for male androgenetic alopecia: A double‐blind randomized clinical trial
Sublingual and oral minoxidil are equally effective for hair growth, but sublingual causes fewer palpitations.
research Clinical Safety and Efficacy of Dual Wavelength Low-Level Light Therapy in Androgenetic Alopecia: A Double-Blind Randomized Controlled Study
Dual wavelength LED caps can safely increase hair density in androgenetic alopecia.
research Australian dermatologists' prescribing behaviours for female androgenetic alopecia
Australian dermatologists often prescribe spironolactone and minoxidil for female hair loss.
research Painful bilateral gynaecomastia secondary to topical finasteride
Topical finasteride can cause breast enlargement and tenderness in men.
research Hair presentation test
The woman's hair loss pattern doesn't match typical conditions like alopecia areata or female pattern hair loss.
research Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss
Low-dose oral minoxidil may help with hair loss, but more research is needed.
research Characterizing Lipid Changes and Use of Lipid-Lowering Medications in Patients With Alopecia Areata Treated With Baricitinib: Integrated Results From the BRAVE-AA1 and -AA2 Clinical Trials
Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.
research 49690 Long-term efficacy of baricitinib in alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2
Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.
research 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
research BH04 A global survey to assess practice of laboratory testing in alopecia areata by hair specialists
Dermatologists vary widely in testing practices for alopecia areata, often exceeding guideline recommendations.
research Dissecting cellulitis of the scalp in a paediatric male
A 13-year-old boy with a rare scalp condition improved significantly with isotretinoin, minoxidil, oral steroids, and antiseptic shampoo.
research Real‐world effectiveness and safety of tofacitinib for alopecia areata: A retrospective cohort study of 202 patients
Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.